EGRX - Eagle Pharmaceuticals, Inc.
61.01 -0.02 (-0.03%)
After hours: 4:11PM EDT
| Previous Close | 61.99 |
| Open | 62.00 |
| Bid | 54.50 x 800 |
| Ask | 73.95 x 900 |
| Day's Range | 60.41 - 62.00 |
| 52 Week Range | 48.84 - 85.66 |
| Volume | 77,396 |
| Avg. Volume | 223,820 |
| Market Cap | 918.862M |
| Beta (3Y Monthly) | 0.16 |
| PE Ratio (TTM) | 31.85 |
| EPS (TTM) | 1.92 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 79.25 |
Markit•10 days agoSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
- Business Wire•15 days ago
Eagle Pharmaceuticals Enters into Agreement with USAMRICD to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) today announced that it has entered into an agreement with the United States Army Medical Research Institute of Chemical Defense (USAMRICD), the nation's leading science and technology laboratory in the area of medical chemical countermeasures research and development, to conduct a study to evaluate the neuroprotective effects of RYANODEX® (dantrolene sodium). The study will be conducted under a Cooperative Research and Development Agreement (CRADA), a written agreement that allows government laboratories to partner with private industries or academia on research and development projects.
- Business Wire•21 days ago
Eagle Pharmaceuticals, Inc. To Present At Cantor Global Healthcare Conference
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
- Business Wire•21 days ago
Eagle Appoints David Pernock to Position of Chief Operating Officer
Eagle Pharmaceuticals, Inc. today announced that the Compensation Committee of the Company’s Board of Directors has approved the appointment of David Pernock to the position of Chief Operating Officer, effective as of September 1, 2018.
Markit•23 days agoSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
- Simply Wall St.•last month
Does Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Fall With The Market?
If you own shares in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
- Zacks•last month
Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod
The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.
- Zacks•last month
Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position
Agios Pharmaceuticals (AGIO) names Dr. Jacqualyn Fouse as its next chief executive officer from Feb 1, 2019 onward.
- Business Wire•last month
Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 16th Annual Global Healthcare Conference
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
- Business Wire•2 months ago
Eagle Pharmaceuticals Concludes Enrollment of Second Safety and Efficacy Study at Hajj to Evaluate RYANODEX for Exertional Heat Stroke
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (EGRX) today announced completion of enrollment of the Company’s second clinical study to further evaluate the safety and efficacy of RYANODEX® (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke (“EHS”), an investigational new indication for the product.
Markit•2 months agoSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind ...
- Business Wire•2 months ago
Eagle Pharmaceuticals Named to Fortune 100 List of Fastest-Growing Companies
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or “the Company”) today announced that the Company has been named to the Fortune 100 List of Fastest-Growing Companies, ranking 16th overall, including achieving the #1 positions for EPS 3-year growth of 392% and revenue 3-year growth of 109%. “We are extremely proud of how our team has executed on our overall growth strategy. Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products.
- Business Wire•2 months ago
Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA
– BENDEKA protected by 16 patents running from 2026 through 2033 –
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of EGRX earnings conference call or presentation 7-Aug-18 12:30pm GMT
Q2 2018 Eagle Pharmaceuticals Inc Earnings Call
Markit•2 months agoSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
- Zacks•2 months ago
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 15.85% and 14.53%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Eagle Pharmaceuticals: 2Q Earnings Snapshot
On a per-share basis, the Woodcliff Lake, New Jersey-based company said it had profit of 17 cents. Earnings, adjusted for non-recurring costs and stock option expense, were 95 cents per share. The specialty ...
- Business Wire•2 months ago
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results
-- Q2 2018 net income was $0.18 per basic and $0.17 per diluted share and adjusted non-GAAP net income of $0.99 per basic and $0.95 per diluted share --
- ACCESSWIRE•2 months ago
Eagle Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...
- Zacks•2 months ago
Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates
Emergent Biosolutions (EBS) rides high on earnings as well as revenue beat in Q2.
- Zacks•2 months ago
Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally
Conatus (CNAT) incurs narrower-than-expected loss in Q2. Sales miss estimates.
- Zacks•3 months ago
NuVasive (NUVA) in Focus: Stock Moves 6.02% Higher
NuVasive (NUVA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Zacks•3 months ago
Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?
Is (EGRX) Outperforming Other Medical Stocks This Year?
- Business Wire•3 months ago
Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2018 Financial Results on August 7, 2018
Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2018 second quarter financial results on Tuesday, August 7, 2018, before the market opens.
